Inhibition in Purified Systems and in Human Plasma of Chimaeric Plasminogen Activators Consisting of the NH₂-Terminal Region of Tissue-Type Plasminogen Activator and the COOH-Terminal Region of UrokinaseType Plasminogen Activator

Summary

Recombinant chimaeric molecules between tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA) or two chain urokinase-type plasminogen activator (tcu-PA) have intact enzymatic properties of scu-PA or tcu-PA towards natural and synthetic substrates (Nelles et al., J Biol Chem 1987; 262: 10855-10862). In the present study, we have compared the reactivity with inhibitors of both the single chain and two chain variants of recombinant u-PA and two recombinant chimaeric molecules between t-PA and scu-PA (t-PA/u-PA-s: amino acids 1-263 of t-PA and 144-411 of u-PA; t-PA/u-PA-e: amino acids 1-274 of t-PA and 138-411 of u-PA). Incubation with human plasma in the absence of a fibrin clot for 3 h at 37° C at equipotent concentrations (50% clot lysis in 2 h), resulted in significant fibrinogen breakdown (to about 40% of the normal value) for all two chain molecules, but not for their single chain counterparts. Preincubation of the plasminogen activators with plasma for 3 h at 37° C, resulted in complete inhibition of the fibrinolytic potency of the two chain molecules but did not alter the potency of the single chain molecules. Inhibition of the two chain molecules occurred with a t_½ of approximately 45 min. The two chain variants were inhibited by the synthetic urokinase inhibitor Glu-Gly-Arg-CH₂CCl with apparent second-order rate constants of 8,000-10,000 M⁻¹s⁻¹, by purified α₂-antiplasmin with second-order rate constants of about 300 M⁻¹s⁻¹, and by plasminogen activator inhibitor-1 (PAI-1) with second-order rate constants of approximately 2 × 10⁷ M⁻¹s⁻¹.

It is concluded that the reactivity of single chain and two chain forms of t-PA/u-PA chimaers with inhibitors is very similar to that of the single and two chain forms of intact u-PA.

Keywords

Chimaeric plasminogen activators - Tissue-type plasminogen activator (t-PA) - Urokinase-type plasminogen activator (u-PA)

• References

• 1 Collen D. Report of the Meeting of the Subcommittee on Fibrinolysis San Diego, CA, July 13, 1985. Thromb Haemostas 1985; 54: 893
• 2 Murano G, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma.. Blood 1980; 55: 430-436
• 3 Moroi M, Aoki KN. Isolation and characterization of alpha₂-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.. J Biol Chem 1976; 251: 5956-5965
• 4 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.. Blood 1984; 64: 907-913
• 5 Collen D. Report of the Meeting of the Subcommittee on Fibrinolysis, Jerusalem, Israel, June 2, 1986.. Thromb Haemostas 1986; 56: 415-416
• 6 Zamarron C, Lijnen HR, Van HoefB, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.. Thromb Haemostas 1984; 52: 19-23
• 7 Panned R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.. Blood 1986; 67: 1215-1223
• 8 Collen D, De CockF, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.. Thromb Haemostas 1984; 52: 24-26
• 9 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.. J Biol Chem 1987; 262: 10855-10862
• 10 Gheysen D, Lijnen HR, Pierard L, de ForestaF, Demarsin E, Jacobs P, De WildeM, Bollen A, Collen D. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator (t-PA) with a truncated single-chain urokinase-type plasminogen activator (scu-PA).. J Biol Chem 1987; 262: 11779-11784
• 11 Lijnen HR, Nelles L, Van HoefB, Demarsin E, Collen D. Characterization of a chimaeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of single chain urokinase-type plasminogen activator (scu-PA).. J Biol Chem. (in press).
• 12 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of recombinant human single-chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of Lys¹⁵⁸.. J Biol Chem 1987; 262: 5682-5689
• 13 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. . Nature 1983; 301: 214-221
• 14 Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.. Thromb Haemostas 1986; 56: 411-414
• 15 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.. Thromb Haemostas 1985; 54: 684-687
• 16 Wiman B. Affinity-chromatographic purification of human alpha₂- antiplasmin.. Biochem J 1980; 191: 229-232
• 17 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin.. Eur J Biochem 1978; 84: 573-578
• 18 Alessi MC, Declerck PJ, De MolM, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).. Eur J Biochem 1988; 175: 531-540
• 19 Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones.. Thromb Res 1984; 34: 431-437
• 20 Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism.. J Biol Chem 1986; 261: 1253-1258
• 21 Astrup T, Miillertz S. The fibrin plate method for estimating fibrinolytic activity.. Arch Biochem Biophys 1952; 40: 346-351
• 22 Fletcher AP, Akjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion.. J Lab Clin Med 1965; 65: 713-731
• 23 Lijnen HR, Van HoefB, Collen D. Differential reactivity of Glu-Gly-Arg-CH₂Cl, a synthetic urokinase inhibitor, with single-chain and two- chain forms of urokinase-type plasminogen activator.. Eur J Biochem 1987; 162: 351-356
• 24 Samama M, Castel M, Matsuo O, Hoylaerts M, Lijnen HR. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.. Thromb Haemostas 1982; 47: 36-40
• 25 Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human a₂-antiplasmin, a serine protease inhibitor (serpin).. J Biol Chem 1987; 262: 1659-1664
• 26 Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Dano K. Plasminogen activator inhibitor type-1 reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-218
• 27 Wiman B, Collen D. On the mechanism of the reaction between human a₂-antiplasmin and plasmin.. J Biol Chem 1979; 254: 9291-9297